Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Stay updated on market trends for ZLDPF. Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names The $200B GLP-1 market ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

Shares of ZLDPF stock opened at $97.78 on Thursday. The company has a market cap of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88. The company has a current ratio of 35.49, a quick ratio ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF) to jointly develop an ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vicarious Surgical (RBOT – Research Report), Alkermes (ALKS ...

Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF).

Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide. The company has a strong cash position of DKK9 billion, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...